Vemurafenib, dabrafenib, and encorafenib are BRAF inhibitors (BRAFi) approved by the US Food and Drug Administration (FDA) to treat patients with BRAFV600E mutated metastatic melanomas [29]. This evidence concerns the gene BRAF and metastatic melanoma.